HOME > 研究実績
連絡先

研究実績
Performance

2016年

  • 森脇健介. 骨粗鬆症の医療経済.骨粗鬆症治療薬クリニカルクエスチョン100.診断と治療社.pp167-168. 2016.
  • 森脇健介. 医療経済からみた骨粗鬆症治療.medicina 53(3)430-433. 2016.
  • 森脇健介. 骨折予防介入の費用対効果. 日本整形外科学会雑誌 90: 205-210. 2016.
  • 泉良太、佐野哲也.脳血管障害患者のEQ-5D-5L視覚評価法に影響を及ぼす因子の解明~回復期リハビリテーション病棟における調査~.QOL J 2016;17(1):56-64.
  • Moriwaki K, Noto S. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan. Osteoporos Int. 2017; 28: 621-632.
  • Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017;28: 643-652.
  • Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Value Health. 2016; 19: 648-54.
  • Nagayama H, Tomori K, Ohno K, Takahashi K, Nagatani R, Izumi R, Moriwaki K, Yamauchi K. Cost effectiveness of the occupation based approach for subacute stroke patients: Result of a randomized controlled trial. Topics in Stroke Rehabilitation 2017; 1-8.
  • Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis International 2017; in press.
  • Fukuda H, Moriwaki K. Cost-effectiveness analysis of safety-engineered devices. Infection Control & Hospital Epidemiology 2016; in press.
  • Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. Value in Health 2016; in press.
  • Noto S, Izumi R, Moriwaki K, Shiroiwa T, Igarashi A, Fukuda T, Ikeda S, Saito S, Ishida H. Comparison Between Eq-5d And Hui In Japanese Population Norms. International Society for Pharmacoeconomics and Outcomes Research 19th Annual European Meeting (Vienna, Austria), 2016.11.4~11.6.
  • Saito S, Noto S, Miyazaki M.Health Utility Measured with EQ-5D-5L in Japanese Patients Undergoing Hemodialysis. ISPOR 7th Asia-Pacific Conference, (Singapore), 2016.9.3~9.6.
  • Fukuda T, Igarashi A, Ishida H, Ikeda S, Saito S, Sakamaki H, Shimozuma K, Shiroiwa T, Takura T, Tomita N, Noto S, Fukuda H, Moriwaki K, Moriyama Y, Akazawa M. Economic Evaluation Guideline for Pharmaceuticals and Medical Devices in Japan. ISPOR 7th Asia-Pacific Conference, (Singapore), 2016.9.3~9.6.
  • Igarashi A, Fukuda T, Kobayashi M, Noto S, Saito S, Shimozuma K, Shiroiwa T, Ikeda S. Application of EQ-5D-5L / EQ-5D-3L to the general public –survey for population norm-. 33rd EuroQol Group Scientific Plenaly, (Berlin, Germany), 2016.9.15~9.16.

2015年

  • 森脇健介.医療経済評価の視点から見る今後の骨・関節疾患.骨・関節・軟骨治療のための新製品開発と臨床ニーズ.情報技術協会.2015.pp3-12.
  • 森脇健介(分担).骨粗鬆症の予防と治療ガイドライン2015年版.骨粗鬆症の予防と治療ガイドライン編集委員会.2015.
  • 森脇健介.骨粗鬆症治療と医療経済評価.最新医学別冊 診断と治療のABC110.骨粗鬆症2015:197-198.
  • 森脇健介.骨粗鬆症の薬物治療と費用対効果の検討.日本臨床2015;73(10):1754-1759.
  • Hirase S, Hasegawa D, Takahashi H, Moriwaki K, Saito A, et al. Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia. Int J Hematol. 2015; 102(5): 594-601.
  • Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, Shimozuma K. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016; 25: 707-19.
  • Shiroiwa T, Saito S, Shimozuma K, Kodama S, Noto S, Fukuda T. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making. Appl Health Econ Health Policy. 2016;14: 375-85.
  • Moriwaki K, Noto S. Validation of fracture risk model in Japanese women compared with FRAX. PRM89. ISPOR 18th Annual European Congress. Milan, Italy. 2015.11.7-11.
  • Noto SIzumi R, Shiroiwa T, Igarashi A, Ikeda S, Fukuda T, Saito S, Shimozuma K, Kobayashi M, Moriwaki K, Ishida H. Comparison Between The Interim Eq-5d-5l Score And The New Japanese Scoring In Stroke Patients. International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Meeting. Milan, Italy. 2015.11.7-11.

2014年

  • 能登真一.医療経済評価における効用値評価-EQ-5D,HUIを中心に-.(財)レギュラトリーサイエンス財団編.基礎から学ぶ医療経済評価.じほう,東京.2014.pp165-179.
  • 能登真一,村井千賀,竹内さをり,岩瀬義昭,中村春基.地域在住の要介護高齢者に対する「生活行為向上マネジメント」を用いた作業療法の効果 多施設共同ランダム化比較試験.作業療法 2014;33:259-269.
  • 池田俊也,白岩健,五十嵐中,能登真一,福田敬,齋藤信也,下妻晃二郎.日本語版EQ-5D-5Lにおけるスコアリング法の開発.保健医療科学 2014;64:47-55.
  • 森脇健介.骨粗鬆症・骨折の医療経済.Clin Calcium 201424(5)711-718
  • 森脇健介.骨量減少症日本人女性に対する骨折予防治療の費用対効果.O.li.v.e.―骨代謝と生活習慣病の連関― 20144(2)90-94
  • Izumi RNoto S, Ikeda S, Fukuda T, Shiroiwa T, Igarashi A. Comparison of three utility measures in stroke patients using item response theory analysis. Niigata Journal of Health and Welfare, 2014; 13 (1): 1-12.
  • 泉良太.健康関連QOLに影響を及ぼすADL因子の検討.QOL J 2014;15(1):11-17.
  • 泉良太能登真一.項目反応理論分析を用いた脳血管障害患者におけるHealth Utilities Index Mark 3の測定特性の検討.医療経済研究 2014;25(2):126-138.
  • Noto S, Murai C, Takeuchi S, Iwase Y, Nakamura H. Long-term effect of using "the management tool for daily life performance”. 16th International Congress of the World Federation of Occupational Therapists. Yokohama, Japan. 2014.6.18-21.
  • Noto S, Shimozuma K, Saito S, Shiroiwa T, Fukuda T, Moriwaki K, Izumi R. A Comparison of Value for Health States Worse Than Dead Between Japan and UK. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Noto S, Izumi R, Moriwaki K. Long-Term Grading of Health-Related Quality of Life of Care-Needed Elderly: A 2-Yr Follow-Up Study. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Moriwaki K, Yoshimura M, Izumi R, Noto S. Cost-Effectiveness of Multiple Anti-Osteoporotic Therapies for Secondary Fracture Prevention in Japan. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Yoshimura M, Moriwaki K, Noto S, Takiguchi T. Health Economic Evaluation of Osteoporosis Screening and Treatment Strategy in the Elderly Japanese Women. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Amsterdam, Netherland. 2014.11.8-12.
  • Izumi R, Noto S, Uemura T. Difference of the health-related quality of life according to a diagnosis of the stroke in recovery phase. 16th International Congress of the World Federation of Occupational Therapists. Yokohama, Japan. 2014.6.18-21.

2013年

  • 能登真一.医療経済からみたリハビリテーションの成果と効果.専門リハ 2013;12:2-6.
  • 能登真一.生活行為向上マネジメントと経済的効果に関する検証.日本作業療法士協会誌 2013;17:28-29.
  • 福田敬, 白岩健, 池田俊也, 五十嵐中, 赤沢学, 石田博, 能登真一, 齋藤信也, 坂巻弘之, 下妻晃二郎, 田倉智之, 福田治久, 森脇健介, 冨田奈穂子, 小林慎.医療経済評価研究における分析手法に関するガイドライン.保健医療科学 2013;62:625-640.
  • Izumi RNoto S, Uemura T, Ikeda S, Fukuda T. Comparison of three utility measures using item response theory analysis in stroke patients. International society of quality of life research 20th annual conference. Miami, FL, USA. 2013.10.9-12.
  • Noto SIzumi RMoriwaki K, Igarashi A, Ikeda S, Fukuda T, Shiroiwa T, Kobayashi M, Saito S, Shimozuma K. Comparing the performance of the EQ-5D-5L with the EQ-5D-3L in stroke patients in Japan. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.
  • Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Toujo T, Inoue H, Fukagawa M, Takahashi HE. Cost-effectiveness analysis of alendronate therapy for secondary prevention of osteoporotic fractures. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.
  • Moriwaki K, Ito S, Kobayashi D, Noto S, Yanagisawa S, Toujou T, Murasawa A . Predicting EQ-5D utility scores from SF-36 scores in patinets with rheumatoid arthritis in Japan. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.
  • Fukuda T, Akazawa M, Fukuda H, Igarashi A, Ikeda S, Ishida H, Kobayashi M, Moriwaki K, Noto S, Sakamaki H, Saito S, Shimozuma K, Shiroiwa T, Takura T, Tomita N. Proposal of economic evaluation guideline in Japan. International society for pharmacoeconomics and outcome research 16th Annual European Congress. Dublin, Ireland. 2012.11.2-6.

2012年

  • Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. Journal of Bone and Mineral Research. 2012; 28(2):395-403. Impact Factor: 6.373 in 2011
  • Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamae I, Fukagawa M. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis. 2012;60(2):262–271. <H.K. and K.M. contributed equally to this work> Impact Factor: 5.434 in 2011
  • Moriwaki K, Noto S. Dynamic simulation analysis for optimal sickbed allocation in a hospital. Journal of Niigata Health and Welfare. 2012;11(1):1-11.
  • Matsuzawa T, Takata T, Yokono K, Ueda H, Moriwaki K, Kamae I, Urakami K, Sakurai T. A warning index used in prescreening for Alzheimer’s disease, based on self-reported cognitive deficits and vascular risk Factors for dementia in elderly patients with type 2 diabetes. International Journal of Alzheimer's Disease. 2012; Article ID 124215, 8 pages
  • 森脇健介(分担翻訳);臨床経済学研究会・ISPOR 日本部会, ISPOR 用語集翻訳委員会. ヘルスケアサイエンスのための医薬経済学用語集.東京:医薬出版センター;2011.
  • 福田敬, 白岩健, 五十嵐中, 小林慎, 池田俊也, 能登真一, 下妻晃二郎, 坂巻弘之.世界で医療経済評価はどのように用いられているか? 7ヶ国の比較調査結果と日本での応用可能性についての検討.医療経済研究 2012;23:147-164.
  • 齋藤信也, 児玉聡, 白岩健, 下妻晃二郎, 能登真一, 後藤玲子.医療資源配分とQALYに関する倫理的側面からの考察.薬剤疫学 2012;17:47-53.
  • 泉良太能登真一,上村隆元.脳疾患患者における健康関連QOL尺度の検討 項目反応理論による識別力・難易度の推定.QOL J 2012;13(1):93-102.
  • Noto S, Uemura T, Moriwaki K. Change in health-related quality of life after occupational therapy in community-dwelling dependent elderly: a randomized controlled trial. International society for Pharmacoeconomics and Outcomes Research 17th Annual European Meeting. Berlin, Germany. 2012.11.5-8.